8-K: OS Therapies Advances Osteosarcoma Drug, Posts Strong Q2

OS Therapies announced positive Phase 2b clinical trial results for OST-HER2 in osteosarcoma, securing FDA RMAT status and a BLA number, alongside a $4.2 million capital raise.

Summary

• Reported second quarter 2025 financial results and provided a business update.
• FDA confirmed OST-HER2 meets the biological definition of Regenerative Medicine Advanced Therapy (RMAT) and issued a Biologics Licensing Application (BLA) number.
• An End of Phase 2 Meeting with the FDA is scheduled for August 27, 2025, to review the Phase 2b clinical trial data.
• The Phase 2b trial for OST-HER2 in recurrent, fully resected, pulmonary metastatic osteosarcoma showed statistically significant 12-month Event Free Survival (EFS) (35% vs. 20%, p = 0.0197) and interim 2-year Overall Survival (OS) (66.6% vs. 40%, p = 0.0046).
• The trial demonstrated a strong safety profile with 0 patients experiencing Grade 4 or Grade 5 treatment-associated adverse events.
• A U.S. commercial partnership with Eversana has been established, positioning OST-HER2 for a possible U.S. launch in the first half of 2026.
• A $4.2 million capital raise was closed on July 11, 2025, via a warrant exercise inducement and exchange offering, extending the cash runway into mid-2026.
• The company is eligible for a Priority Review Voucher (PRV) if a BLA for OST-HER2 is received prior to September 30, 2026; recent PRV sales were valued at $160 million (June 2025) and $155 million (May 2025).
• International regulatory progress includes an Innovative Licensing and Access Pathway (ILAP) submission to the UK's MHRA and a scheduled October 2025 rapporteur meeting with the European Medicines Agency (EMA).
• A new U.S. Patent was granted, providing exclusivity for the new commercial manufacturing process for the listeria cancer immunotherapy platform through 2040.
• The listeria cancer immunotherapy platform was acquired from Ayala Pharmaceuticals, expanding the pipeline with 4 clinical-stage and 8 preclinical-stage candidates.
• A subsidiary, OS Animal Health, was formed to explore strategic alternatives for OST-HER2 in canine osteosarcoma.
• NYSE American-listed OSTX common stock was included in the Russell Microcap, Russell Microcap Value, and Russell Microcap Growth indexes.
• An At-The-Market (ATM) offering sales agreement was entered into, enabling the company to raise up to $18 million in gross proceeds.

Sentiment

Score: 8

Explanation: The filing presents highly positive clinical trial data, significant regulatory advancements (RMAT, BLA number, accelerated approval path), a strategic commercial partnership, and a capital raise that extends the cash runway. While the net loss increased, the overall progress on the lead asset and pipeline expansion are very strong indicators for a clinical-stage biotech.

Positives

• Statistically significant positive Phase 2b clinical trial results for OST-HER2, showing 12-month Event Free Survival of 35% vs. 20% (p=0.0197) and interim 2-year Overall Survival of 66.6% vs. 40% (p=0.0046).
• Strong safety profile with no Grade 4 or 5 treatment-associated adverse events reported in the Phase 2b trial.
• FDA confirmed Regenerative Medicine Advanced Therapy (RMAT) status and issued a Biologics Licensing Application (BLA) number for OST-HER2, indicating advanced regulatory progress.
• Established a U.S. commercial partnership with Eversana, positioning OST-HER2 for an anticipated launch in the first half of 2026.
• Eligibility for a Priority Review Voucher (PRV) upon BLA approval, with recent PRV sales valued at $160 million, offering significant non-dilutive funding potential.
• Successfully closed a $4.2 million capital raise, extending the cash runway into mid-2026.
• Expanded the company's pipeline significantly through the acquisition of the listeria cancer immunotherapy platform, including 4 clinical-stage and 8 preclinical-stage candidates.
• Granted a new U.S. Patent for the listeria cancer immunotherapy platform's manufacturing process, providing exclusivity through 2040.
• Made substantial international regulatory progress with ILAP submission to MHRA (UK) and a scheduled rapporteur meeting with EMA (Europe).
• Inclusion of OSTX common stock in the Russell Microcap, Russell Microcap Value, and Russell Microcap Growth indexes.
• Formed OS Animal Health subsidiary, expanding potential applications of OST-HER2 beyond human osteosarcoma.

Negatives

• Net operating loss increased to $4.537 million in the second quarter of 2025, compared with $1.557 million in the second quarter of 2024, primarily due to increased regulatory activities.

Risks

• Dependency on the successful outcome of the End of Phase 2 Meeting with the FDA and subsequent Biologics Licensing Application (BLA) submission and approval for OST-HER2.
• Uncertainty regarding the timing and success of regulatory approvals in the U.S., UK, and Europe.
• Reliance on the potential sale of a Priority Review Voucher for significant non-dilutive funding, which is contingent on BLA approval by a specific date.
• Need for additional capital beyond mid-2026 to fund ongoing operations and development activities.
• Risks inherent in clinical trials, including the possibility of unexpected adverse events or failure to replicate results in larger or post-market studies.
• Competition from other companies developing treatments for osteosarcoma and other solid tumors.
• General risks and uncertainties described in the Company's most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.

Future Outlook

OS Therapies anticipates initiating a rolling Biologics Licensing Application (BLA) submission for OST-HER2 in late Q3 2025, targeting potential U.S. and U.K. regulatory approval as early as year-end 2025. The company expects a U.S. launch of OST-HER2 in the first half of 2026 and aims to sell a Priority Review Voucher, potentially valued at over $160 million, if BLA approval is secured by September 30, 2026. International regulatory processes are also underway with scheduled meetings with the MHRA and EMA, aiming for synchronized approval processes.

Management Comments

• "Gained significant momentum in the second quarter as we began to make meaningful clinical and regulatory progress on our path towards bringing the first new treatment for osteosarcoma to market in the United States in the last 40 years." Paul Romness, MPH, Chairman & CEO
• "Updated interim 2-year overall survival data readout that shows a statistically significant benefit for OST-HER2 treated patients, coupled with the final 12-month Event Free Survival (EFS) that also shows statistically significant benefit for OST-HER2 treated patients, from our Phase 2b trial." Paul Romness, MPH, Chairman & CEO
• "The congruence between the overall survival and EFS data gives our clinical and regulatory teams confidence that we are on strong footing as we march towards our goal of receiving a Biologics Licensing Application (BLA) by the U.S. Food and Drug Administration (FDA) for OST-HER2 under the Accelerated Approval Program." Paul Romness, MPH, Chairman & CEO
• "Our U.S. commercial partnership with Eversana positions us to be able to bring OST-HER2 to osteosarcoma patients in the first half of 2026." Paul Romness, MPH, Chairman & CEO
• "So long as we receive a BLA for OST-HER2 prior to September 30, 2026, the Company is eligible to be granted a priority review voucher (PRV)... we believe that the PRV market is likely to continue to see an increase in value moving forward." Paul Romness, MPH, Chairman & CEO
• "Made progress internationally with our recent Innovative Licensing and Access Pathway (ILAP) submission... MHRA recommends a synchronization of the approval process with the FDA via Project Orbis within 30 days of the BLA submission." Paul Romness, MPH, Chairman & CEO
• "Scheduled an October 2025 rapporteur meeting with the European Medicines Agency (EMA) as the starting point for the approval process with Europe." Paul Romness, MPH, Chairman & CEO

Industry Context

This announcement highlights significant progress in the rare pediatric oncology space, specifically for osteosarcoma, a disease that has seen no new treatments in 40 years. OS Therapies' focus on immunotherapy and Antibody Drug Conjugates (ADCs) aligns with broader industry trends towards targeted and immune-based cancer therapies. The pursuit of accelerated approval pathways and international regulatory synchronization (Project Orbis) reflects a common strategy for biotech companies developing treatments for unmet medical needs, aiming to expedite market access. The acquisition of a broader listeria cancer immunotherapy platform also positions the company for future pipeline expansion in a competitive oncology landscape.

Comparison to Industry Standards

• OST-HER2's Phase 2b results, showing statistically significant 12-month Event Free Survival (35% vs. 20%, p=0.0197) and interim 2-year Overall Survival (66.6% vs. 40%, p=0.0046) compared to historical control at MIB Factor, represent a substantial improvement for a disease that has not seen a new treatment in 40 years. This is a critical benchmark given the high unmet medical need in osteosarcoma.
• The strong safety profile with zero Grade 4 or 5 treatment-associated adverse events is a positive indicator, especially when compared to the often severe side effects associated with traditional chemotherapy regimens used in cancer treatment.
• The FDA's confirmation of Regenerative Medicine Advanced Therapy (RMAT) status and issuance of a Biologics Licensing Application (BLA) number for OST-HER2 positions it favorably for accelerated approval, a pathway typically reserved for therapies addressing serious conditions with unmet medical needs and demonstrating potential for substantial improvement over existing therapies. This is comparable to other RMAT-designated therapies that have successfully navigated expedited regulatory pathways.
• The potential eligibility for a Priority Review Voucher (PRV), valued at $160 million in recent transactions, aligns with the incentives provided by the FDA for developing treatments for rare pediatric diseases, a mechanism utilized by other companies like BioMarin Pharmaceutical Inc. (for Brineura) or Sarepta Therapeutics (for Exondys 51) to monetize their rare disease drug development efforts.

Stakeholder Impact

• **Shareholders**: Positive impact due to strong clinical data, accelerated regulatory pathway, potential for significant PRV sale, and extended cash runway, which could lead to increased share value. Dilution risk from ATM offering.
• **Patients (Osteosarcoma)**: Highly positive impact as OST-HER2 shows statistically significant benefit and strong safety, offering the first new treatment option in 40 years for a rare and aggressive cancer, with potential market availability in H1 2026.
• **Employees**: Positive impact due to company progress, pipeline expansion, and potential for commercialization, indicating job security and growth opportunities.
• **Regulatory Authorities (FDA, MHRA, EMA)**: Collaboration through RMAT, BLA, ILAP, and Project Orbis demonstrates commitment to bringing innovative therapies to market efficiently.
• **Commercial Partners (Eversana)**: Strengthened partnership with clear path to U.S. launch, indicating potential for revenue generation.
• **Creditors**: Improved financial stability due to recent capital raise and potential PRV sale, reducing immediate liquidity concerns.

Next Steps

• End of Phase 2 Meeting with FDA scheduled for August 27, 2025.
• Projected initiation of rolling BLA submission for OST-HER2 in late Q3 2025.
• Rapporteur meeting with EMA scheduled for October 2025.
• Potential regulatory approval for OST-HER2 in the U.S. and U.K. as early as year-end 2025.
• Expected U.S. launch of OST-HER2 in the first half of 2026.
• Sale of Priority Review Voucher if BLA is received prior to September 30, 2026.
• Further development of the acquired listeria cancer immunotherapy platform.
• Exploration of strategic alternatives for OS Animal Health.

Key Dates

Recommendation

The filing reveals exceptionally strong clinical data for OST-HER2, demonstrating statistically significant improvements in both Event Free Survival and Overall Survival for osteosarcoma, a disease with a critical unmet need. The rapid regulatory progress, including FDA RMAT designation, a BLA number, and an accelerated approval pathway, significantly de-risks the lead asset. The potential for a $160 million Priority Review Voucher sale provides a substantial non-dilutive funding source. Coupled with a recent $4.2 million capital raise extending the cash runway and a strategic commercial partnership for a projected H1 2026 launch, the company is well-positioned for near-term value creation. While the net loss increased, it is attributable to necessary regulatory activities for a product nearing commercialization. The overall outlook is highly favorable for a clinical-stage biotech.

Keywords

Osteosarcoma, Cancer Immunotherapy, Biotechnology, ADC, OST-HER2, FDA Approval, RMAT, BLA, Clinical Trial, Phase 2b, Orphan Drug, Rare Pediatric Disease, Priority Review Voucher, Eversana, Listeria, Oncology, Drug Development, Biologics, NYSE American, OSTX